EUVIMEDEUVIMED entdecken
Crossref

Performance of Fentanyl Immunoassays in an ED Patient Population

Catherine M Mills, Parker C Dryja, Elizabeth Champion-Lyons, Charles Keppler, Nikolina Babic iD

The Journal of Applied Laboratory Medicine · 2024

DOI: 10.1093/jalm/jfae022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2024. Verfasst von Catherine M Mills und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC 29425, United States. Hauptthemen laut MEDLINE: Fentanyl, Emergency Service, Hospital, Substance Abuse Detection. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fentanyl is a synthetic opioid fueling the current opioid crisis in the United States. While emergency department (ED) visits due to opioid-related overdoses, injection complications, and withdrawals become increasingly more frequent, fentanyl is not detected in routine toxicology testing. We evaluated 2 FDA-approved fentanyl immunoassays in a sampled ED population.

Methods

De-identified, remnant urine specimens (n = 213) collected from patients presenting to a large ED were analyzed using ARK Fentanyl II (ARK II) and Immunalysis SEFRIA (SEFRIA) fentanyl immunoassays on an Architect c16000 (Abbott) analyzer. All discrepant specimens were evaluated by LC-MS/MS. Additionally, polysubstance abuse patterns and trends were analyzed.

Results

While intra-assay imprecision was comparable for ARK II and SEFRIA, inter-assay imprecision for ARK II and SEFRIA varied from 8.0% to 1.8% and from 37% to 12.5%, respectively. SEFRIA had a marginally higher false-positivity rate (3%) than ARK II (1%). Both assays had equivalent sensitivity of 95%, with ARK II (99%) having greater specificity than SEFRIA (97%). Fentanyl was detected in 13.7% of drug-panel-positive patient samples and most frequently observed in patients also testing positive for amphetamines and cocaine. Notably, fentanyl was detected in 5.3% of patient samples that were negative for all other drugs in our standard toxicology panel.

Conclusions

A sizable portion of drug-positive samples from our ED were positive for fentanyl, with a subset of patients testing positive for fentanyl alone. Implementation of fentanyl testing into routine toxicology panels can elucidate polysubstance abuse paradigms and capture ED patients that would go undetected in standard panels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FentanylEmergency Service, HospitalSubstance Abuse DetectionHumansImmunoassayFemaleMaleAdultSensitivity and SpecificityTandem Mass SpectrometryAnalgesics, OpioidMiddle AgedReproducibility of ResultsOpioid-Related DisordersChromatography, Liquid

Substanzen

FentanylAnalgesics, Opioid

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC 29425, United States.
  • Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, SC 29425, United States.

ORCID-Profile: Nikolina Babic

Zitieren

APA

Mills, C. M., Dryja, P. C., Champion-Lyons, E., Keppler, C., & Babic, N. (2024). Performance of Fentanyl Immunoassays in an ED Patient Population. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfae022

Vancouver

Mills CM, Dryja PC, Champion-Lyons E, Keppler C, Babic N. Performance of Fentanyl Immunoassays in an ED Patient Population. The Journal of Applied Laboratory Medicine. 2024. doi:10.1093/jalm/jfae022

BibTeX
@article{Mills2024,
  author = {Mills, Catherine M and Dryja, Parker C and Champion-Lyons, Elizabeth and Keppler, Charles and Babic, Nikolina},
  title = {Performance of Fentanyl Immunoassays in an ED Patient Population},
  journal = {The Journal of Applied Laboratory Medicine},
  year = {2024},
  doi = {10.1093/jalm/jfae022}
}
Kostenlos starten →